NASDAQ:GLUE Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis → Elon Musk’s Final Masterpiece: “X-9840” (From Paradigm Press) (Ad) Free GLUE Stock Alerts $3.98 -0.21 (-5.01%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share Today's Range$3.90▼$4.1250-Day Range$3.98▼$7.8652-Week Range$2.44▼$8.84Volume215,700 shsAverage Volume169,049 shsMarket Capitalization$201.04 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Monte Rosa Therapeutics alerts: Email Address Monte Rosa Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside176.4% Upside$11.00 Price TargetShort InterestBearish5.98% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.92) to ($1.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.60 out of 5 starsMedical Sector831st out of 903 stocksBiological Products, Except Diagnostic Industry143rd out of 152 stocks 3.3 Analyst's Opinion Consensus RatingMonte Rosa Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMonte Rosa Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Monte Rosa Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted5.98% of the float of Monte Rosa Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonte Rosa Therapeutics has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.Change versus previous monthShort interest in Monte Rosa Therapeutics has recently increased by 20.94%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMonte Rosa Therapeutics does not currently pay a dividend.Dividend GrowthMonte Rosa Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLUE. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Monte Rosa Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for GLUE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Monte Rosa Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.50% of the stock of Monte Rosa Therapeutics is held by insiders.Percentage Held by Institutions79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Monte Rosa Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($1.92) to ($1.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monte Rosa Therapeutics is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monte Rosa Therapeutics is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonte Rosa Therapeutics has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Monte Rosa Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About Monte Rosa Therapeutics Stock (NASDAQ:GLUE)Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Read More GLUE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLUE Stock News HeadlinesJune 10 at 1:54 AM | americanbankingnews.comHead to Head Review: Inhibrx (NASDAQ:INBX) & Monte Rosa Therapeutics (NASDAQ:GLUE)May 31, 2024 | americanbankingnews.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest UpdateMay 30, 2024 | globenewswire.comMonte Rosa Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 30, 2024 | globenewswire.comMonte Rosa Therapeutics Announces Leadership Team PromotionsMay 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Aerovate Therapeutics (AVTE)May 21, 2024 | globenewswire.comMonte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel DiseaseMay 18, 2024 | uk.investing.comMonte Rosa Therapeutics sets public offering at $4.70 per shareMay 16, 2024 | globenewswire.comMonte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public OfferingMay 15, 2024 | globenewswire.comMonte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Monte Rosa Therapeutics Amidst Promising Drug Pipeline and Stable FinancialsMay 10, 2024 | finance.yahoo.comMonte Rosa Therapeutics Reports Q1 2024 Financial Results: A Detailed OverviewMay 9, 2024 | investorplace.comGLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | globenewswire.comMonte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 4, 2024 | finanznachrichten.deMonte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific OfficerMay 2, 2024 | finance.yahoo.comMonte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific OfficerMay 2, 2024 | globenewswire.comMonte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific OfficerMarch 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)March 19, 2024 | finance.yahoo.comWall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should KnowMarch 16, 2024 | finance.yahoo.comMonte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial ResultsMarch 15, 2024 | finance.yahoo.comIs Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?March 14, 2024 | markets.businessinsider.comPromising Clinical Progress and Strategic Milestones Bolster Buy Rating for Monte Rosa TherapeuticsMarch 14, 2024 | investorplace.comGLUE Stock Earnings: Monte Rosa Therapeutics Misses EPS for Q4 2023March 14, 2024 | finanznachrichten.deMonte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 14, 2024 | benzinga.comMonte Rosa Therapeutics: Q4 Earnings InsightsMarch 14, 2024 | globenewswire.comMonte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateSee More Headlines Receive GLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/09/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:GLUE CUSIPN/A CIK1826457 Webwww.monterosatx.com Phone617-949-2643FaxN/AEmployees133Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+176.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,350,000.00 Net MarginsN/A Pretax Margin-12,674.91% Return on Equity-74.13% Return on Assets-49.14% Debt Debt-to-Equity RatioN/A Current Ratio4.82 Quick Ratio4.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.58 per share Price / Book1.11Miscellaneous Outstanding Shares50,510,000Free Float47,229,000Market Cap$201.03 million OptionableOptionable Beta1.41 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Markus Warmuth M.D. (Age 52)President, CEO & Director Comp: $901.35kDr. Owen B. Wallace Ph.D. (Age 55)Chief Scientific Officer Comp: $630.68kDr. Filip Janku M.D. (Age 49)Ph.D., Chief Medical Officer Comp: $658.66kMs. Jennifer ChampouxChief People & Operations OfficerDr. Sharon Townson Ph.D. (Age 49)Chief Technology Officer Dr. John C. Castle Ph.D. (Age 52)Chief Data & Information Officer Mr. Andrew FunderburkSenior VP and Head of IR & Strategic FinanceMr. Philip Nickson J.D. (Age 45)Ph.D., General Counsel Mr. Magnus Walter DPHILSenior Vice President of Drug DiscoveryMr. Edmund Dunn (Age 58)Vice President & Corporate Controller More ExecutivesKey CompetitorsInvivydNASDAQ:IVVDKinnate BiopharmaNASDAQ:KNTEbluebird bioNASDAQ:BLUESeres TherapeuticsNASDAQ:MCRBKronos BioNASDAQ:KRONView All CompetitorsInstitutional OwnershipPrice T Rowe Associates Inc. MDBought 155,880 shares on 5/15/2024Ownership: 10.091%EntryPoint Capital LLCBought 15,893 shares on 5/14/2024Ownership: 0.031%Vanguard Group Inc.Bought 47,412 shares on 5/10/2024Ownership: 3.250%Acadian Asset Management LLCBought 26,687 shares on 5/10/2024Ownership: 0.110%View All Institutional Transactions GLUE Stock Analysis - Frequently Asked Questions Should I buy or sell Monte Rosa Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Monte Rosa Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GLUE shares. View GLUE analyst ratings or view top-rated stocks. What is Monte Rosa Therapeutics' stock price target for 2024? 3 Wall Street analysts have issued 1 year target prices for Monte Rosa Therapeutics' shares. Their GLUE share price targets range from $11.00 to $11.00. On average, they expect the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 176.4% from the stock's current price. View analysts price targets for GLUE or view top-rated stocks among Wall Street analysts. How have GLUE shares performed in 2024? Monte Rosa Therapeutics' stock was trading at $5.65 at the beginning of the year. Since then, GLUE shares have decreased by 29.6% and is now trading at $3.98. View the best growth stocks for 2024 here. Are investors shorting Monte Rosa Therapeutics? Monte Rosa Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 2,310,000 shares, an increase of 20.9% from the April 30th total of 1,910,000 shares. Based on an average trading volume of 167,200 shares, the short-interest ratio is presently 13.8 days. Approximately 6.0% of the shares of the stock are short sold. View Monte Rosa Therapeutics' Short Interest. When is Monte Rosa Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our GLUE earnings forecast. How were Monte Rosa Therapeutics' earnings last quarter? Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) posted its quarterly earnings results on Thursday, May, 9th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.03. The company had revenue of $1.06 million for the quarter, compared to the consensus estimate of $4.29 million. When did Monte Rosa Therapeutics IPO? Monte Rosa Therapeutics (GLUE) raised $211 million in an initial public offering on Thursday, June 24th 2021. The company issued 11,700,000 shares at a price of $17.00-$19.00 per share. Who are Monte Rosa Therapeutics' major shareholders? Monte Rosa Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (10.09%), Vanguard Group Inc. (3.25%), Acadian Asset Management LLC (0.11%) and EntryPoint Capital LLC (0.03%). Insiders that own company stock include Cormorant Asset Management, Lp and Versant Venture Capital Vi, L. How do I buy shares of Monte Rosa Therapeutics? Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GLUE) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
